FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2620987799> ?p ?o ?g. }

• W2620987799 endingPage "758" @default.
• W2620987799 startingPage "757" @default.
• W2620987799 abstract "Empirical ovarian stimulation with gonadotropin or clomiphene is the standard therapy for women with unexplained infertility. Use of these agents, however, is often complicated by the ovarian hyperstimulation syndrome, multiple gestations, an increased risk of preterm birth, and associated neonatal morbidity. A number of studies have reported that an aromatase inhibitor, letrozole, may be an effective alternative for ovarian stimulation in couples with unexplained infertility. This agent has been used successfully to induce ovulation in women with the polycystic ovary syndrome, a leading cause of infertility. There have been reports of a similar or improved pregnancy rate with letrozole as compared with gonadotropin or clomiphene. Letrozole has been associated with monofollicular development in most patients, which may result in enhanced fertility, a reduced risk of ovarian hyperstimulation, and multiple births compared with gonadotropin and clomiphene. Moreover, its administration has not been associated with a significantly increased risk of congenital anomalies. This multicenter randomized trial assessed whether ovarian stimulation with letrozole would result in a lower rate of multiple gestation while maintaining live birth rates as compared with clomiphene or gonadotropin. The study was conducted at 12 clinical sites throughout the United States. Study subjects were 900 couples with unexplained infertility. Women were between 18 and 40 years of age with regular menses, had a normal uterine cavity with at least 1 patent fallopian tube, and had a male partner with semen that met the intrauterine insemination threshold for normal sperm counts. Women were randomly assigned to ovarian stimulation (up to 4 cycles) with gonadotropin (n = 301) clomiphene (n = 300), or letrozole (n = 299). Gonadotropin was administered by subcutaneous injection, and clomiphene or letrozole was administered orally as coated tablets. The primary outcome, multiple gestation among women with pregnancies, was compared first between the letrozole group and the overall standard-therapy group (clomiphene and gonadotropin groups combined) and then among the 3 groups. A placebo control group was not used. Treatment with gonadotropin, clomiphene, or letrozole resulted in clinical pregnancies in 35.5%, 28.3%, and 22.4% of cycles and live birth in 32.2%, 23.3%, and 18.7%, respectively. Pregnancy rates with letrozole were significantly lower than the rates with gonadotropin or clomiphene (P = 0.003) or gonadotropin alone (P < 0.001) but not with clomiphene alone (P = 0.10). The multiple gestation rate with letrozole among ongoing pregnancies with fetal heart activity (13% [9/67 pregnancies]) did not differ significantly from the rate with gonadotropin or clomiphene (22% [42/192]; P = 0.15) or clomiphene alone (9.4% [8/85]; P = 0.44) but was lower than the rate with gonadotropin alone (32% [34/107]; P = 0.006). All multiple gestations in the clomiphene and letrozole groups were twins; gonadotropin treatment resulted in 24 twin and 10 triplet gestations. There were no significant differences among the 3 groups in the frequencies of congenital anomalies or major fetal and neonatal complications. Ovarian stimulation with letrozole in women with unexplained infertility results in a significantly lower frequency of multiple gestation but a lower frequency of live birth, as compared with gonadotropin but not clomiphene. These data support continued use of clomiphene as first-line therapy for couples with unexplained infertility." @default.
• W2620987799 created "2017-06-09" @default.
• W2620987799 creator A5006555524 @default.
• W2620987799 creator A5007340619 @default.
• W2620987799 creator A5009719215 @default.
• W2620987799 creator A5013117782 @default.
• W2620987799 creator A5028985571 @default.
• W2620987799 creator A5037540780 @default.
• W2620987799 creator A5041440078 @default.
• W2620987799 creator A5042644813 @default.
• W2620987799 creator A5045463023 @default.
• W2620987799 creator A5053242908 @default.
• W2620987799 creator A5055948110 @default.
• W2620987799 creator A5060972453 @default.
• W2620987799 creator A5068153450 @default.
• W2620987799 creator A5069339514 @default.
• W2620987799 creator A5070081966 @default.
• W2620987799 creator A5077144143 @default.
• W2620987799 creator A5077246875 @default.
• W2620987799 creator A5080024227 @default.
• W2620987799 creator A5080121869 @default.
• W2620987799 creator A5080156928 @default.
• W2620987799 creator A5086164230 @default.
• W2620987799 creator A5086459592 @default.
• W2620987799 creator A5087479096 @default.
• W2620987799 creator A5088388829 @default.
• W2620987799 date "2015-12-01" @default.
• W2620987799 modified "2023-09-27" @default.
• W2620987799 title "Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility" @default.
• W2620987799 doi "https://doi.org/10.1097/ogx.0000000000000275" @default.
• W2620987799 hasPublicationYear "2015" @default.
• W2620987799 type Work @default.
• W2620987799 sameAs 2620987799 @default.
• W2620987799 citedByCount "1" @default.
• W2620987799 countsByYear W26209877992023 @default.
• W2620987799 crossrefType "journal-article" @default.
• W2620987799 hasAuthorship W2620987799A5006555524 @default.
• W2620987799 hasAuthorship W2620987799A5007340619 @default.
• W2620987799 hasAuthorship W2620987799A5009719215 @default.
• W2620987799 hasAuthorship W2620987799A5013117782 @default.
• W2620987799 hasAuthorship W2620987799A5028985571 @default.
• W2620987799 hasAuthorship W2620987799A5037540780 @default.
• W2620987799 hasAuthorship W2620987799A5041440078 @default.
• W2620987799 hasAuthorship W2620987799A5042644813 @default.
• W2620987799 hasAuthorship W2620987799A5045463023 @default.
• W2620987799 hasAuthorship W2620987799A5053242908 @default.
• W2620987799 hasAuthorship W2620987799A5055948110 @default.
• W2620987799 hasAuthorship W2620987799A5060972453 @default.
• W2620987799 hasAuthorship W2620987799A5068153450 @default.
• W2620987799 hasAuthorship W2620987799A5069339514 @default.
• W2620987799 hasAuthorship W2620987799A5070081966 @default.
• W2620987799 hasAuthorship W2620987799A5077144143 @default.
• W2620987799 hasAuthorship W2620987799A5077246875 @default.
• W2620987799 hasAuthorship W2620987799A5080024227 @default.
• W2620987799 hasAuthorship W2620987799A5080121869 @default.
• W2620987799 hasAuthorship W2620987799A5080156928 @default.
• W2620987799 hasAuthorship W2620987799A5086164230 @default.
• W2620987799 hasAuthorship W2620987799A5086459592 @default.
• W2620987799 hasAuthorship W2620987799A5087479096 @default.
• W2620987799 hasAuthorship W2620987799A5088388829 @default.
• W2620987799 hasConcept C121608353 @default.
• W2620987799 hasConcept C126322002 @default.
• W2620987799 hasConcept C131872663 @default.
• W2620987799 hasConcept C2776166826 @default.
• W2620987799 hasConcept C2777391703 @default.
• W2620987799 hasConcept C2777688143 @default.
• W2620987799 hasConcept C2777702977 @default.
• W2620987799 hasConcept C2778580812 @default.
• W2620987799 hasConcept C2778782382 @default.
• W2620987799 hasConcept C2778812593 @default.
• W2620987799 hasConcept C2779234561 @default.
• W2620987799 hasConcept C2779306644 @default.
• W2620987799 hasConcept C2781065240 @default.
• W2620987799 hasConcept C2781230225 @default.
• W2620987799 hasConcept C29456083 @default.
• W2620987799 hasConcept C3018442814 @default.
• W2620987799 hasConcept C512716672 @default.
• W2620987799 hasConcept C530470458 @default.
• W2620987799 hasConcept C54355233 @default.
• W2620987799 hasConcept C71315377 @default.
• W2620987799 hasConcept C71924100 @default.
• W2620987799 hasConcept C86803240 @default.
• W2620987799 hasConceptScore W2620987799C121608353 @default.
• W2620987799 hasConceptScore W2620987799C126322002 @default.
• W2620987799 hasConceptScore W2620987799C131872663 @default.
• W2620987799 hasConceptScore W2620987799C2776166826 @default.
• W2620987799 hasConceptScore W2620987799C2777391703 @default.
• W2620987799 hasConceptScore W2620987799C2777688143 @default.
• W2620987799 hasConceptScore W2620987799C2777702977 @default.
• W2620987799 hasConceptScore W2620987799C2778580812 @default.
• W2620987799 hasConceptScore W2620987799C2778782382 @default.
• W2620987799 hasConceptScore W2620987799C2778812593 @default.
• W2620987799 hasConceptScore W2620987799C2779234561 @default.
• W2620987799 hasConceptScore W2620987799C2779306644 @default.
• W2620987799 hasConceptScore W2620987799C2781065240 @default.
• W2620987799 hasConceptScore W2620987799C2781230225 @default.
• W2620987799 hasConceptScore W2620987799C29456083 @default.
• W2620987799 hasConceptScore W2620987799C3018442814 @default.

• next